Risks associated with cognitive function and management strategies in the clinical use of ADT: a systematic review from clinical and preclinical studies

• Published in: Supportive care in cancer Vol. 32; no. 8; p. 561
• Main Authors: Cui, Meng-fan, Chen, Li-ming, Jiang, Cindy, Ma, Bing-zhe, Yuan, Fu-wen, Zhao, Chen, Liu, Shi-min
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.08.2024; Springer Nature B.V
• Subjects: Cognitive ability; Endocrine therapy; Health risks; Medicine; Medicine & Public Health; Nursing; Nursing Research; Oncology; Pain Medicine; Prostate cancer; Rehabilitation Medicine; Review; Side effects; ADT; Androgens; Cognitive function; Prostate cancer
• ISSN: 0941-4355; 1433-7339; 1433-7339
• DOI: 10.1007/s00520-024-08753-3

Prostate cancer is one of the most common malignancies and a leading cause of death in men. Owing to its excellent anti-tumor effects, androgen deprivation therapy (ADT) is widely used in the treatment of prostate cancer. However, its use is controversial because of its potential for inducing cognitive decline. In this review, we summarized the findings of preclinical and clinical studies investigating the effects of ADT on cognitive function in prostate cancer. We discussed the methods used to assess cognitive function in these studies, elucidated the mechanisms through which ADT affects cognitive function, and highlighted recent advancements in cognitive assessment methods. The findings of this review serve as a valuable reference for examining the relationship between ADT and cognitive function in future studies. Besides, the findings may help clinicians understand the advantages and disadvantages of ADT and optimize the treatment plan so as to minimize the adverse effects of ADT.